Part 1: The symposium focuses on cases where proprietary rights on research inputs are posing, or may imminently pose, obstacles to biopharmaceutical R & D. Many of these cases involve diseases that have limited market potential, either because the affected population is poor or because it is small. Hence the need to reduce costs related to licensing, as well as other R & D costs, is particularly acute. These concerns may especially affect genomic innovation, where the ability to "invent around" building blocks of knowledge may be limited.

Part 2: The symposium focuses on cases where proprietary rights on research inputs are posing, or may imminently pose, obstacles to biopharmaceutical R&D. Many of these cases involve diseases that have limited market potential, either because the affected population is poor or because it is small. Hence the need to reduce costs related to licensing, as well as other R&D costs, is particularly acute. These concerns may especially affect genomic innovation, where the ability to "invent around" building blocks of knowledge may be limited.

Invited speakers and subsequent panel presentations and discussions on economic aspects of drug development for developing countries.

Recorded on March 19, 2003.

Full title: Dr. Robin Hood?: Creating Incentives to Make Medicines & Vaccines for Diseases in Resource-Poor Countries.

Commercialization of Human Genomics. Panel 3, Reframing the Intellectual Property Debate: Gene Patenting and Policy Options

Recorded on September 28, 2002.

Appearing: Karen Magri (Myers, Bigel, Sibley & Sajovec), moderator ; Arti Rai (University of Pennsylvania Law School), Sharon Terry (President, Genetic Alliance, Inc., Washington DC), Robert Cook-Deegen (Duke University), panelists.

Panel discussion on the implications of protection of genomic data.

Recorded on September 28, 2002.

Panel titled: Genomic Data: Publication, Access & Secrecy.

Conference title: Commercialization of Human Genomics: Consequences for Science & Humanity (Commercialization of Human Genomics (2002))

Appearing: Elizabeth Kiss (Duke University), Peter Newmark (BioMed Centeral), Daniel Drell (Department of Energy), Jerome Reichman (Duke Law) and Allen E. Buchanan (Duke University).

Commercialization of Human Genomics. Panel 1, Political Philosophy and Economy of Intellectual Property

Recorded on September 27, 2002.

Appearing: Katherine Bartlett (Duke University School of Law), conference introduction; Lauren Dame (Duke University School of Law), panel introduction; Noah Pickus (Institute for Emerging Issues, NCSU), moderator; Alex Rosenberg (Duke University), Max N. Wallace (Cogent Neuroscience, Inc., NC), James Boyle (Duke University School of Law), panelists.

Commercialization of Human Genomics. Panel 2, Biotech Patenting and the Common Good

Recorded on September 27, 2002.

Appearing: Kevin Schulman (Duke University), moderator; Barbara Caulfield (Affymetrix, Inc., Santa Clara, CA), Lila Feisse (Biotechnology Industry Organization, Washington DC), Patrick Terry (President PXE International, Inc., Washington DC), panelists.